Ginkgo Bioworks Holdings Debt to Equity Ratio 2020-2022 | DNA

Current and historical debt to equity ratio values for Ginkgo Bioworks Holdings (DNA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Ginkgo Bioworks Holdings debt/equity for the three months ending March 31, 2022 was 0.02.
Ginkgo Bioworks Holdings Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-03-31 $0.44B $1.61B 0.28
2021-12-31 $0.50B $1.57B 0.32
2021-09-30 $0.53B $1.62B 0.33
2021-06-30 $1.72B $0.01B 344.20
2021-03-31 $1.72B $0.01B 344.59
2020-12-31 $0.00B 0.00
2020-09-30 $0.00B $0.00B 0.00
2019-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.228B $0.314B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00